A notable example of CAR-T cell therapy is Kymriah (tisagenlecleucel), which is approved by the FDA for treating acute lymphoblastic leukemia (ALL) in pediatric and young adult patients.399 Kymriah targets the CD19 antigen, which is commonly expressed on B-cell malignancies. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.